These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9699092)

  • 1. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study.
    Mertes G
    Diabetes Res Clin Pract; 1998 Apr; 40(1):63-70. PubMed ID: 9699092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.
    Mertes G
    Diabetes Res Clin Pract; 2001 Jun; 52(3):193-204. PubMed ID: 11323089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
    Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
    Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
    Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
    Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study.
    Spengler M; Cagatay M
    Clin Invest Med; 1995 Aug; 18(4):325-31. PubMed ID: 8549020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
    Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
    J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTECT interim results: a large multicenter study of patients with type II diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies.
    Baron A; Neumann C
    Clin Ther; 1997; 19(2):282-95. PubMed ID: 9152567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of beano on the tolerability and pharmacodynamics of acarbose.
    Lettieri JT; Dain B
    Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.
    Balfour JA; McTavish D
    Drugs; 1993 Dec; 46(6):1025-54. PubMed ID: 7510610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance].
    Gendeleka GF
    Lik Sprava; 1997; (6):105-7. PubMed ID: 9589946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR
    Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies.
    Buse J; Hart K; Minasi L
    Clin Ther; 1998; 20(2):257-69. PubMed ID: 9589817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of acarbose treatment of NIDDM].
    Wainstein J; Jedwab M
    Harefuah; 1997 Feb; 132(4):258-63, 311. PubMed ID: 9153894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acarbose: a review of US clinical experience.
    Coniff R; Krol A
    Clin Ther; 1997; 19(1):16-26; discussion 2-3. PubMed ID: 9083705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acarbose: can it take a bite out of type 2 diabetes mellitus?
    Ponte CD
    Ann Pharmacother; 1996 Nov; 30(11):1333-5. PubMed ID: 8913419
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
    Pan CY; Landen H
    Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
    Domke A; Willms B
    Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.